Fig. 5.

DITPA potentiates OPC cycle exit promoting differentiation in enriched OL cultures derived from NKX2.1-GFP + sorted hESCs.

(a) DITPA treatment (10 ng/mL) regime throughout Stage VI. Cells were treated with either T₃ alone (T₃, 50 ng/mL), DITPA alone (DITPA, 10 ng/mL) or T₃ with DITPA (T₃, 50 ng/mL + DITPA, 10 ng/mL) then these were analyzed on day 7 and 21 post-treatments by flow cytometry and qRT-PCR. (b) Flow cytometric dot plots upon BrdU incorporation at day 7 of treatments (Ap; apoptotic cells). (c) The percentage of cells at the different cell cycle stages at day 7 and 21 post-treatments. (d) The percentage of cells in S phase (BrdU-positive) for the different treatment groups are shown. (e–g) qRT-PCR analyses of cell cycle-associated genes; (e) CDKN1B, (f) TP53 and (g) TNFRSF2, 7 and 21 days post-treatments. (h) Flow cytometric analysis of O4 at day 7 post-treatments. (i) The percentage of O4 + cells analyzed by flow cytometry at day 7 and 21 post-treatments. (j–l) qRT-PCR analyses of myelin genes; (j) MYT1, (k) PLP1, (l) MBP, 7 and 21 days post-treatments. (m and n) qRT-PCR analyses of TH transporter genes; (m) SLC16A2 (MCT8), and (n) SLC16A10 (MCT10) 7 and 21 days post-treatments. *P < 0.05; **P < 0.01; ***P < 0.001; (n = 3; mean ± SEM).